Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | CNR1 | P21554 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | F7 | P08709 | 3/20 | 0.67 |
| ▸ | F3 | P13726 | 3/20 | 0.67 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | PPARD | Q03181 | 2/20 | 0.67 |
| ▸ | PPARA | Q07869 | 2/20 | 0.67 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.67 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581393 | 1.00 | MEN1 (0.69) | MEN1KMT2AALDH1A1HPGDCNR1 | |
| SCHEMBL23280891 | 1.00 | MEN1 (0.69) | MEN1KMT2AALDH1A1HPGDCNR1 | |
| SCHEMBL18736051 | 0.98 | MEN1 (0.67) | MEN1KMT2AALDH1A1HPGDCNR1 | |
| SCHEMBL3634728 | 0.95 | CNR1 (0.71) | MEN1KMT2AALDH1A1HPGDCNR1 | |
| SCHEMBL3634730 | 0.95 | CNR1 (0.71) | MEN1KMT2AALDH1A1HPGDCNR1 | |
| SCHEMBL16011353 | 0.95 | TERT (0.63) | MEN1KMT2ATDP1MAPTBLM | |
| SCHEMBL18251107 | 0.95 | TERT (0.63) | MEN1KMT2ATDP1MAPTBLM | |
| SCHEMBL379107 | 0.95 | TERT (0.63) | MEN1KMT2ATDP1MAPTBLM | |
| SCHEMBL4147472 | 0.95 | TERT (0.63) | MEN1KMT2ATDP1MAPTBLM | |
| SCHEMBL23027735 | 0.95 | TERT (0.63) | MEN1KMT2ATDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267680-A1 | FLUORESCENT DYES | Exopharm Limited (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| WO-2022133552-A1 | FLUORESCENT DYES | Exopharm Limited (AU) | 2022-06-30 | — | — | WO | disclosed |
| EP-3960726-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3597644-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2020191329-A1 | ARAMID AMPHIPHILE SELF-ASSEMBLED NANOSTRUCTURES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3603648-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | Shionogi & Co., Ltd (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110372593-A | Cannabinoid receptor antagonists/iN. V. erse agonists | 詹里恩探索公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110290809-A | Pharmaceutical dosage form comprising TASK-1 and TASK-3 channel inhibitor and its purposes for treating respiratory disorder | 拜耳制药股份公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110191884-A | Substituted 6- (1H-pyrazol-1-yl) pyrimidine-4-amine derivatives and uses thereof | 拜耳公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-101223184-B | Glucuronidated nebivolol | MYLAN LAB INC | 2012-10-10 | — | — | CN | disclosed |
| CN-102711739-A | bilayer tablet | BRISTOL MYERS SQUIBB CO | 2012-10-03 | — | — | CN | disclosed |
| CN-102188708-A | Compositions containing nebivolol | MYLAN LAB INC | 2011-09-21 | — | — | CN | disclosed |
| CN-101880276-A | Diazepan compounds as the replacement of orexin receptor antagonists | MERCK & CO INC | 2010-11-10 | — | — | CN | disclosed |
| CN-101627028-A | Substituted diazepan compounds as orexin receptor antagonists | MERCK & CO INC | 2010-01-13 | — | — | CN | disclosed |
| CN-101490024-A | Substituted phenylacetic acids as DP-2 antagonists | ICOS CORP (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-101277960-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | disclosed |
| US-6852315-B2 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030040090-A1 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | AGRICULTURE, UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2003-02-27 | — | — | US | disclosed |
| US-6485949-B1 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | MEN1 1693/4885KMT2A 1076/4885ALDH1A1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.